Metabolic and inflammatory risk reduction in response to lipid-lowering and lifestyle modification in the medically underserved individuals

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer (R01 HL63895)
  • Daiichi-Sankyo (R01 HL63895)
  • National Heart, Lung, and Blood Institute (R01 HL63895)
  • AstraZeneca (R01 HL63895)
  • Abbott Laboratories (R01 HL63895)
  • Merck (R01 HL63895)
  • Novartis (R01 HL63895)
  • National Institutes of Health (R01 HL63895)
  • Pfizer Foundation (R01 HL63895)
  • Amgen (R01 HL63895)
  • Daiichi Sankyo Co Ltd (R01 HL63895)

This publication has 17 references indexed in Scilit: